Efineptakin alfa + Pembrolizumab
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High Grade Astrocytic Tumor
Conditions
High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
Trial Timeline
Jan 24, 2023 → Oct 15, 2028
NCT ID
NCT05465954About Efineptakin alfa + Pembrolizumab
Efineptakin alfa + Pembrolizumab is a phase 2 stage product being developed by Merck for High Grade Astrocytic Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05465954. Target conditions include High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma.
What happened to similar drugs?
3 of 20 similar drugs in High Grade Astrocytic Tumor were approved
Approved (3) Terminated (6) Active (12)
🔄olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05465954 | Phase 2 | Recruiting |
Competing Products
20 competing products in High Grade Astrocytic Tumor